

RSC Chemical Biology

rsc.li/rsc-chembio



ISSN 2633-0679

PAPER

Edward W. Tate *et al.*
Discovery of potent and selective activity-based probes
(ABPs) for the deubiquitinating enzyme USP30



Cite this: *RSC Chem. Biol.*, 2024, 5, 439

Discovery of potent and selective activity-based probes (ABPs) for the deubiquitinating enzyme USP30[†]

Milon Mondal,^{‡a} Fangyuan Cao,^{‡a} Daniel Conole,^{§a} Holger W. Auner,^{¶b} and Edward W. Tate^{§*a}

Ubiquitin-specific protease 30 (USP30) is a deubiquitinating enzyme (DUB) localized at the mitochondrial outer membrane and involved in PINK1/Parkin-mediated mitophagy, pexophagy, BAX/BAK-dependent apoptosis, and IKK β -USP30-ACLY-regulated lipogenesis/tumorigenesis. A USP30 inhibitor, **MTX652**, has recently entered clinical trials as a potential treatment for mitochondrial dysfunction. Small molecule activity-based probes (ABPs) for DUBs have recently emerged as powerful tools for in-cell inhibitor screening and DUB activity analysis, and here, we report the first small molecule ABPs (**IMP-2587** and **IMP-2586**) which can profile USP30 activity in cells. Target engagement studies demonstrate that **IMP-2587** and **IMP-2586** engage active USP30 at nanomolar concentration after only 10 min incubation time in intact cells, dependent on the presence of the USP30 catalytic cysteine. Interestingly, proteomics analyses revealed that DESI1 and DESI2, small ubiquitin-related modifier (SUMO) proteases, can also be engaged by these probes, further suggesting a novel approach to develop DESI ABPs.

Received 29th January 2024,
Accepted 7th March 2024

DOI: 10.1039/d4cb00029c

rsc.li/rsc-chembio

Introduction

Decoration of proteins with the small protein modifier ubiquitin (Ub) is a reversible post translation modification (PTM) that regulates almost all cellular functions including proteolysis, transcriptional regulation, cellular trafficking, localization, inflammation, and autophagy.¹ Hundreds of Ub ligases and deubiquitinases (DUBs) are involved in the addition or removal of ubiquitin, respectively, and modulation of this system has emerged as an important therapeutic strategy across many diseases.² Ubiquitin specific peptidase 30 (USP30) is a member of the USP DUB family, which typically harbours a Cys-His-Asp catalytic triad.³ USP30 is the only DUB known to be present in the outer mitochondrial membrane due to its unique transmembrane domain.⁴ USP30 deubiquitylates specific mitochondrial

proteins preferentially by cleaving Lys6-linked ubiquitin chains and opposes mitophagy driven by the E3 ligase Parkin.^{5–8} It has recently been shown that USP30 can also antagonise basal mitophagy mediated by the Parkinson's disease-associated kinase PINK1, even in cells which do not express Parkin.⁹ Overexpression of USP30 and dysregulation in mitochondrial turnover has been associated with neurodegenerative diseases including Parkinson's disease, Alzheimer's disease and motor neuron disease.^{10–12} USP30 may also play a role in drug resistant lymphoma, leukaemia, multiple myeloma, and BAX/BAK-dependent apoptosis.³ USP30 depletion sensitizes cancer cells to BH3-mimetics (*e.g.*, ABT-737), making it a potential target for cancer therapy.⁸ The USP30 inhibitor MTX652 entered clinical trials recently for Acute Kidney Injury, after exhibiting protective outcomes in various preclinical models.¹³ Despite being important therapeutic target and ongoing clinical trials of USP30 inhibitors, the endogenous substrates of USP30 have yet to be firmly established *in vivo* and regulation of its activity remains only partly understood.

Ub-derived activity-based probes (Ub-ABPs) bearing varied electrophilic warheads have been explored to better understand the function and mechanism of DUBs as well as for DUB inhibitor screening.¹¹ While these Ub-ABPs are widely used and have greatly expanded our knowledge of DUB biology, they can be applied only in cell lysate due to their lack of cell permeability.¹⁴ In contrast, ABPs based on small molecules offer complementary properties since they are readily cell

^a Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, 82 Wood Lane, London, W12 0BZ, UK. E-mail: e.tate@imperial.ac.uk

^b Department of Immunology and Inflammation, Imperial College London, Du Cane Road, London, W12 0NN, UK

[†] Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4cb00029c>

[‡] M. M. and F. C. contributed equally to this work.

[§] Current address: Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand.

[¶] Current address: Service and Central Laboratory of Hematology, University Hospital of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland.



permeable, and whilst selective probes are challenging to develop they can be powerful tools to profile DUB activity in live cells, which is helpful to uncover their function in health and disease.^{15,16} Moreover, they have the potential to identify off-targets of structurally-related DUB inhibitors, which is not possible with highly DUB-specific Ub-ABPs.¹⁷

Several USP30 inhibitors based on *N*-cyanopyrrolidine (CNPy), oxospiramilactone, benzenesulfonamides, and naphthylsulfonamide have been reported recently,^{18–20} and in the recent patent literature.^{21–25} However, no ABP specific for USP30 has been developed to date, limiting opportunities to profile USP30 activity in intact cells. Here we report the first small molecule ABPs which target USP30 in an activity-dependent manner and demonstrate their application to identify active DUBs in cancer cells by activity-based protein profiling (ABPP).

Results

To identify a suitable ABP scaffold for USP30, we considered several reported covalent USP30 inhibitors with low nanomolar potency, prioritising those bearing a CNPy warhead, expected to react with the DUB active site cysteine residue to form an isothiourea adduct.^{16,26} We synthesised CNPy **1** (Fig. 1 and Scheme S1, ESI†) which has a reported IC₅₀ of 1–10 nM against USP30²⁵ (following 30 minutes incubation), and designed ABP (**2**, which we named **IMP-2587**) (Fig. 1 and Scheme 1) bearing a terminal alkyne functionality, based on reported structure–activity relationship (SAR) data suggesting that *meta* substitution on the aryl ring would retain activity, and compatibility with bioorthogonal click chemistry. **IMP-2587** was synthesised through a short synthetic route (Scheme 1a). In parallel, we explored a CNPy with a different scaffold, synthesising the highly potent CNPy-bearing covalent inhibitor **3** (Fig. 1 and Scheme S1, ESI†) with reported IC₅₀ value = 1.5 nM against USP30¹⁸ (following 30 minutes incubation), and high biochemical selectivity for

USP30 among a diverse set of DUB family members, although with some appreciable off-target specificity against USP6 at higher concentration.¹⁸ We designed ABP **IMP-2586** based on **3**. For installation of the affinity handle (azide), the reported SAR supported *para* substitution at the terminal aryl ring, so we synthesised **4** by a short synthetic route (Scheme 1b). An azide bioorthogonal tag was preferred in this case due to the problematic instability of an alkyne in this relatively electron rich position during pyrrolidine Boc deprotection.

We first confirmed biochemical inhibition of USP30 with our probes in a fluorescence polarisation (FP) assay using a TAMRA labelled Lys-Gly dipeptide linked to ubiquitin *via* an isopeptide bond (Ub-Lys(TAMRA)-Gly). USP30 (5 nM) was incubated across a concentration series of test compound for 30 min, followed by FP measurement after addition of Ub-Lys(TAMRA)-Gly (100 nM). **IMP-2587** showed IC₅₀ value of 12.6 nM (95% CI 10.7–14.7 nM) against USP30, whereas parent inhibitor **1** showed IC₅₀ value of 18.3 nM (95% CI 11.9–32.7 nM). **IMP-2586** displayed IC₅₀ value of 16.3 nM (95% CI 10.0–28.8 nM), while the original inhibitor **3** showed IC₅₀ value of 4.8 nM (95% CI 3.5–6.3 nM) (Fig. 1 and Fig. S1, ESI†). Cross-screening of **IMP-2587** and **IMP-2586** against an unrelated DUB (UCHL1) displayed no activity (Table S1, ESI†).


We further characterised inhibition kinetics for ABPs in a FP assay using Ub-Lys(TAMRA)-Gly. k_{obs}/I , K_i and k_{inact} determination assay was performed using 30 nM USP30 and 100 nM Ub-Lys(TAMRA)-Gly as described in ESI,† Section S3.1.c. FP was monitored kinetically over an hour after addition of the substrate, and response curves fitted to $y = (v_i/k_{\text{obs}}) (1 - \exp(-k_{\text{obs}}x))$ to calculate k_{obs}/I , 5680 (95% CI = 4723–6638) M⁻¹ s⁻¹ for **IMP-2587**, and 3021 (95% CI = 2350–3693) M⁻¹ s⁻¹ for **IMP-2586** (Fig. S1, ESI†). K_i and k_{inact} were estimated by nonlinear regression to $k_{\text{obs}} = k_{\text{inact}}/(1 + (K_i/x))$ for probes **IMP-2587** (K_i 42.8 nM, k_{inact} 0.0014 s⁻¹) and **IMP-2586** (K_i 5.6 nM and k_{inact} 0.00067 s⁻¹), confirming robust covalent inhibition activity and affinity for these ABPs (Fig. S1, ESI†).

We next determined cellular engagement of endogenous USP30 with **IMP-2587** or **IMP-2586**. HEK293T cells were treated with ABPs for 1 hour followed by western blot analysis of in-lysate competitive activity-based profiling against hemagglutinin-tagged Ub-vinyl methyl ester probe (HA-Ub-VME) (Fig. 2a). In-cell concentration-dependent competition by **IMP-2587** and **IMP-2586** for USP30 were confirmed below 100 nM probe (Fig. 2b and c), whilst engagement of an exemplar unrelated DUB, UCHL1, occurred only at a much higher concentration (30 000 nM). We hypothesise that incomplete modification of USP30 by HA-Ub-VME is likely due to limited retention of USP30 activity in cell lysates, which have likely had the USP30 transmembrane domain compromised, highlighting the potential utility of a small molecule USP30 ABP applicable directly in intact cells. Direct USP30 target engagement by **IMP-2587** and **IMP-2586** was confirmed in HEK293T cells following 1 h probe treatment followed by cell lysis and CuAAC bio-orthogonal ligation to capture reagent azido-TAMRA-biotin (AzTB) for **IMP-2587** or alkyne-TAMRA-biotin for **IMP-2586** (Fig. 3a).²⁷ In-gel fluorescence revealed one major band at *ca.* 60 kDa for **IMP-2587** starting as low as 3 nM probe, with



Fig. 1 Chemical structure of parent compounds and activity-based probes with their determined IC₅₀ and K_i accordingly. Fluorescent Polarisation assay were performed for IC₅₀ (30 minutes incubation against USP30), k_{obs}/I , and k_{inact}/K_i determination of **IMP-2587**, and **IMP-2586** against USP30 using Ub-Lys(TAMRA)-Gly (Fig. S1, ESI†).





Scheme 1 Synthetic route to the compounds described in this work. (a) synthetic route to compound **2 (IMP-2587)**; (b) synthetic route to compound **4 (IMP-2586)**.



Fig. 2 (a) Workflow of immunoblot analysis of HA-Ub-VME USP30 labelling following HEK293T treatment with **IMP-2587** (b) and **IMP-2586** (c) for 1 h. Dose-dependent competition for USP30 labelling occurs for both the ABPs but not with UCHL1 at similar concentration range.

some labelling of additional bands above 30 nM (Fig. 3b). Similarly, labelling with **IMP-2586** revealed a major band at *ca.* 60 kDa, but in this case in-gel fluorescence showed a degree of unspecific labelling across all concentrations, including the vehicle (DMSO)-treated control (Fig. 3d). This unspecific background labelling is

presumably due to the previously reported higher off-target CuAAC reactivity of an alkyne-bearing capture reagent, applied here due to incorporation of an azide tag in **IMP-2586**.²⁸ Moreover, the labelling of USP30 was further confirmed by biotin pulldown and immunoblotting. USP30 was enriched at 10 nM probe and





Fig. 3 USP30 activity profiling using **IMP-2587** and **IMP-2586** in HEK293 cells. (a) Affinity pull-down and chemical proteomics workflow. Cells were incubated with **IMP-2587** and **IMP-2586** for 1 hour, separately and labelled proteins ligated via CuAAC to AzRB or AzT for **IMP-2587** and YnB or YnT for **IMP-2586** for in-gel fluorescence and/or affinity enrichment for immunoblotting and proteomics. Total cell lysates are labelled as TL samples; supernatants following affinity enrichment were collected as SN samples; protein bound to the beads was collected as PD samples. (b) In-gel fluorescence shows dose-dependent labelling by **IMP-2587**. (c) Probe-labelled (**IMP-2587**) protein identification by enrichment and immunoblotting for USP30. (TL: Total Lysate, SN: Supernatant, PD: Pull-Down) (d) In-gel fluorescence shows dose-dependent labelling by **IMP-2586**. (e) Probe-labelled (**IMP-2586**) protein identification by enrichment and immunoblotting for USP30.

maximal at 100 nM, resulting in almost complete engagement and enrichment with both **IMP-2587** and **IMP-2586** (Fig. 3c and e), which was in stark contrast to the ~50% USP30 engagement observed with the Ub-based probe, HA-Ub-VME (Fig. 2b and c).

To validate these probes as ABPs, we sought to demonstrate dependence on USP30 catalytic activity for cellular target engagement, and specificity for the active site Cys residue among the > 20 Cys residues present in USP30. We expressed HA-tagged wild-type (WT) USP30 and active site cysteine to serine mutant (CS) in

HEK293T cells (Fig. 4a). Cells were treated by **IMP-2587** or **IMP-2586** for 10 min or pre-treated with corresponding parent inhibitors for 1 hour followed by probe treatment. Western blot analysis of affinity enriched USP30 demonstrates that USP30 labelling for both probes requires the presence of the catalytic cysteine, and this enrichment can be readily outcompeted by the parent inhibitors (Fig. 4b and c), confirming the activity-dependence of these ABPs.

To explore the selectivity of **IMP-2587** and **IMP-2586** across the whole proteome, we performed quantitative activity-based





Fig. 4 (a) Workflow of HA-tagged USP30 WT or C77S transfection system and **IMP-2587/IMP-2586** labelling in HEK293T cells. HEK293T cells were transfected to overexpress HA-tagged USP 30 WT or catalytic CS mutants, and pull-down following treatment with **IMP-2587** (b) or **IMP-2586** (c) for 10 min. (PD: Pull-Down, TL: Total Lysate).

protein profiling (ABPP) in HEK293T cells following treatment with **IMP-2587** or **IMP-2586** (Fig. 3a). After ABP incubation, cells were lysed, and probe-labelled proteins were ligated to biotinylated capture reagents.²⁷ Incubation of cells with 30 nM probe for 10 min showed highly significant enrichment of USP30 (Fig. 5a and c and Tables S2 and S4, ESI^{\dagger}), consistent with results from in-gel fluorescence (Fig. 3) and pull-down data (Fig. 3 and 4). USP30 was outcompeted by corresponding parent inhibitors for each ABP (Fig. 5b and d and Tables S3 and S5, ESI^{\dagger}), confirming the high potency and rapid engagement of **IMP-2587** and **IMP-2586** in cells. Interestingly, we also observed less potent but still significant enrichment of two desumoylating isopeptidases (DESI1 and DESI2), which were further validated by pull-down immunoblot analyses (Fig. 5e–h). DESI1 and DESI2 are small ubiquitin-related modifier (SUMO) proteases,^{3,29–32} and **IMP-2587** and **IMP-2586** may offer a starting point for future development of DESI ABPs.

Discussion

Small molecule DUB ABPs circumvent the limitations of Ub-based ABPs, which can only be applied in cell lysates. Cell lysis may disrupt native DUB activity resulting in inconsistent and potentially misleading engagement by Ub-ABPs, as seen in the present study in the incomplete modification of USP30 by HA-Ub-VME. In contrast, recently developed pan-DUB small molecule ABPs enable exploration of DUB activity in intact cells, and assessment of cellular target engagement and selectivity of novel inhibitors.^{15,33}

Dysregulation of USP30 is implicated in a range of rare genetic mitochondrial diseases, and neurodegenerative diseases including Parkinson's disease.¹² Accordingly, there is

significant interest in developing USP30 inhibitors for the clinic, and Mission Therapeutics initiated the first clinical trials of a USP30 inhibitor in 2022 for muscular, cardiac and kidney pathologies,³⁴ reporting encouraging Phase I safety data. Selective and potent small molecule USP30 ABPs would be useful tools to explore the role of USP30 activity in intact cells for these diseases.

In this work, we designed, synthesised and validated two novel USP30 ABPs bearing a CNPy. Cyanoamines, particularly CNPy, have been established as a privileged warhead class for DUBs, which have proven challenging to target selectively with other warhead classes (*e.g.* chloroacetamides).^{3,16,26,33,35,36} Recent reports have shown that minimal CNPy probes lacking an extended structure lose activity toward DUBs, suggesting that the scaffold beyond the warhead plays a key role in enabling covalent DUB active site modification, and in selectivity within the DUB family.²⁶ Interestingly, **IMP-2586** and **IMP-2587** showed very similar selectivity for USP30 in cells despite their divergent scaffolds. Unlike most reported DUB ABPs, **IMP-2586** bears an azide tag rather than a terminal alkyne. Given the prevalence and convenience of Boc protecting group chemistry in CNPy synthetic routes, this design choice overcomes problems of acid instability of an electron rich alkyne in this position. Despite reduced CuAAC bioorthogonal ligation specificity using an alkyne capture reagent (Fig. 3), the utility of **IMP-2586** as a selective USP30 ABP is preserved in cellular studies.

Our data suggest that both parent inhibitors from which **IMP-2587** and **IMP-2586** are derived also target DESI1 and DESI2 in cells and these may need to be considered as off-targets where related compounds are used as inhibitors. Like DUBs, DESIs are cysteine proteases, but catalyse hydrolysis of SUMO modifications rather than Ub.²⁹ No probe or inhibitor has been reported to date for DESIs, although these enzymes





Fig. 5 Chemical proteomic analysis of **IMP-2587** at 30 nM (a) or 100 nM (b) and **IMP-2586** at 30 nM (c) or 100 nM (d) labelling in HEK293T cells. Volcano plots showing log₂ difference (fold change) and significance ($-\log p$ -value) between protein enrichment compared to DMSO control (two sample *t* test, $n = 3$, permutation-based FDR = 0.05, $S_0 = 0.1$). Black dots represent non-DUBs, red dots represent DUBs and blue dots represent DESIs. Probe-labelled protein identification by enrichment and immunoblotting in HEK293T cells for DESI1 with **IMP-2587** (e) and **IMP-2586** (f) treatment for 10 min or DESI2 with **IMP-2587** (g) and **IMP-2586** (h) treatment for 10 min. (TL: Total Lysate, PD: Pull-Down).

are reported to be involved in a wide range of cellular pathways, including PI3K/AKT/mTOR signalling and P53-induced apoptosis.^{30,31} Future optimisation of **IMP-2586** and **IMP-2587** to minimise USP30 activity may provide the first ABPs for studying DESIs.

Conclusions

IMP-2586 and **IMP-2587** enable sensitive and rapid detection of USP30 activity in intact cells at probe concentrations as low as 3–10 nM following 1 hour incubation, or 30 nM at 10 min

incubation. Parent inhibitors **1** and **3**, **IMP-2587** and **IMP-2586**, also showed high inhibitory potency against USP30 with low nM IC₅₀ and fast USP30 modification kinetics both biochemically and in cells. Low nanomolar cellular target engagement and selectivity were examined with a range of orthogonal approaches, including HA-Ub-VME ABP assays, and analysis of direct target engagement through CuAAC bio-orthogonal ligation, in-gel fluorescence, enrichment, immunoblotting and ABPP proteomics. Both probes are strictly activity-based and selective for the active site cysteine of USP30 for labelling among the 21 Cys residues present in USP30.



In summary, **IMP-2586** and **IMP-2587** represent the first potent and selective ABPs to explore USP30 activity in intact cells, with the potential to facilitate studies of USP30 biology and target engagement, supporting future development of appropriate therapeutic strategies.

Data availability

The MS data from this publication have been deposited to the ProteomeXchange Consortium *via* the PRIDE partner repository and assigned the identifier PXD044792.

Conflicts of interest

E. W. T. is a founding director and shareholder of Myricx Pharma Ltd., an advisor of and holds share options in Sasmara Therapeutics and receives current or recent funding from Myricx Pharma Ltd, Pfizer Ltd, Kura Oncology, AstraZeneca, Merck & Co., GSK.

Acknowledgements

M. M. was supported by a grant from The European Commission (H2020 Marie Skłodowska Curie Individual Fellowship grant 840690). F. C. and E. W. T. acknowledge funding support from the Laboratory for Synthetic Chemistry and Chemical Biology under the Health@InnoHK Program of The Government of Hong Kong Special Administrative Region of the People's Republic of China. E. W. T. and H. W. A. acknowledge support from the Cancer Research UK Imperial Centre at Imperial College London (A25147). We are grateful to Robin Ketteler for informative discussions on this work.

References

- 1 D. Komander and M. Rape, *Annu. Rev. Biochem.*, 2012, **81**, 203–229.
- 2 J. A. Harrigan, X. Jacq, N. M. Martin and S. P. Jackson, *Nat. Rev. Drug Discovery*, 2018, **17**, 57–77.
- 3 F. Wang, Y. Gao, L. Zhou, J. Chen, Z. Xie, Z. Ye and Y. Wang, *Front. Pharmacol.*, 2022, **13**, 851654.
- 4 M. J. Clague, S. Urbé and D. Komander, *Nat. Rev. Mol. Cell Biol.*, 2019, **20**, 338–352.
- 5 A. Hoshino, W. J. Wang, S. Wada, C. McDermott-Roe, C. S. Evans, B. Gosis, M. P. Morley, K. S. Rath, J. Li, K. Li, S. Yang, M. J. McManus, C. Bowman, P. Potluri, M. Levin, S. Damrauer, D. C. Wallace, E. L. F. Holzbaur and Z. Arany, *Nature*, 2019, **575**, 375–379.
- 6 B. Bingol, J. S. Tea, L. Phu, M. Reichelt, C. E. Bakalarski, Q. Song, O. Foreman, D. S. Kirkpatrick and M. Sheng, *Nature*, 2014, **510**, 370–375.
- 7 C. N. Cunningham, J. M. Baughman, L. Phu, J. S. Tea, C. Yu, M. Coons, D. S. Kirkpatrick, B. Bingol and J. E. Corn, *Nat. Cell Biol.*, 2015, **17**, 160–169.
- 8 J. Liang, A. Martinez, J. D. Lane, U. Mayor, M. J. Clague and S. Urbé, *EMBO Rep.*, 2015, **16**, 618–627.
- 9 E. Marcassa, A. Kallinos, J. Jardine, E. V. Rusilowicz-Jones, A. Martinez, S. Kuehl, M. Islinger, M. J. Clague and S. Urbé, *EMBO Rep.*, 2018, **19**, e45595.
- 10 B. Bingol and M. Sheng, *Free Radical Biol. Med.*, 2016, **100**, 210–222.
- 11 E. Tsefou, A. S. Walker, E. H. Clark, A. R. Hicks, C. Luft, K. Takeda, T. Watanabe, B. Ramazio, J. M. Staddon, T. Briston and R. Ketteler, *Biochem. J.*, 2021, **478**, 4099–4118.
- 12 T. S. Z. Fang, Y. Sun, A. C. Pearce, S. Eleuteri, M. Kemp, C. A. Luckhurst, R. Williams, R. Mills, S. Almond, L. Burzynski, N. M. Márkus, C. J. Lelliott, N. A. Karp, D. J. Adams, S. P. Jackson, J. F. Zhao, I. G. Ganley, P. W. Thompson, G. Balmus and D. K. Simon, *Nat. Commun.*, 2023, **14**, 7295.
- 13 Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury–Mission Therapeutics, accessed 19 February 2024, <https://missiontherapeutics.com/mission-therapeutics-announces-us-fda-approval-to-initiate-phase-ii-clinical-trial-of-its-lead-asset-mtx652-in-acute-kidney-injury/>.
- 14 D. S. Hewings, J. A. Flygare, M. Bogyo and I. E. Wertz, *FEBS J.*, 2017, **284**, 1555–1576.
- 15 J. A. Ward, L. McLellan, M. Stockley, K. R. Gibson, G. A. Whitlock, C. Knights, J. A. Harrigan, X. Jacq and E. W. Tate, *ACS Chem. Biol.*, 2016, **11**, 3268–3272.
- 16 N. Panyain, A. Godinat, T. Lanyon-Hogg, S. Lachiondo-Ortega, E. J. Will, C. Soudy, M. Mondal, K. Mason, S. Elkhallifa, L. M. Smith, J. A. Harrigan and E. W. Tate, *J. Am. Chem. Soc.*, 2020, **142**, 12020–12026.
- 17 J. A. Ward, A. Pinto-Fernandez, L. Cornelissen, S. Bonham, L. Diaz-Sáez, O. Riant, K. V. M. Huber, B. M. Kessler, O. Feron and E. W. Tate, *J. Med. Chem.*, 2020, **63**, 3756–3762.
- 18 E. V. Rusilowicz-Jones, J. Jardine, A. Kallinos, A. Pinto-Fernandez, F. Guenther, M. Giurrandino, F. G. Barone, K. McCarron, C. J. Burke, A. Murad, A. Martinez, E. Marcassa, M. Gersch, A. J. Buckmelter, K. J. Kayser-Bricker, F. Lamoliatte, A. Gajbhiye, S. Davis, H. C. Scott, E. Murphy, K. England, H. Mortiboys, D. Komander, M. Trost, B. M. Kessler, S. Ioannidis, M. K. Ahlijanian, S. Urbé and M. J. Clague, *Life Sci. Alliance*, 2020, **3**, e202000768.
- 19 W. Yue, Z. Chen, H. Liu, C. Yan, M. Chen, D. Feng, C. Yan, H. Wu, L. Du, Y. Wang, J. Liu, X. Huang, L. Xia, L. Liu, X. Wang, H. Jin, J. Wang, Z. Song, X. Hao and Q. Chen, *Cell Res.*, 2014, **24**, 482–496.
- 20 A. F. Kluge, B. R. Lagu, P. Maiti, M. Jaleel, M. Webb, J. Malhotra, A. Mallat, P. A. Srinivas and J. E. Thompson, *Bioorg. Med. Chem. Lett.*, 2018, **28**, 2655–2659.
- 21 M. L. Stockley and M. I. Kemp, WO2018234775A1, 2018.
- 22 M. I. Kemp, M. Stockley and A. Jones, US2018/0194724A1, 2018.
- 23 M. I. Kemp and M. D. Woodrow, WO2017109488A1, 2017.
- 24 K. R. Gibson, A. Jones, M. I. Kemp, A. Madin, M. L. Stockley, G. A. Whitlock and M. D. Woodrow, WO2017141036A1, 2017.
- 25 M. L. Stockley, M. I. Kemp, A. Madin, M. D. Woodrow and A. Jones, WO2018/060689A1, 2018.



- 26 C. Grethe, M. Schmidt, G.-M. Kipka, R. O'Dea, K. Gallant, P. Janning and M. Gersch, *Nat. Commun.*, 2022, **13**, 5950.
- 27 E. M. Storck, J. Morales-Sanfrutos, R. A. Serwa, N. Panyain, T. Lanyon-Hogg, T. Tolmachova, L. N. Ventimiglia, J. Martin-Serrano, M. C. Seabra, B. Wojciak-Stothard and E. W. Tate, *Nat. Chem.*, 2019, **11**, 552–561.
- 28 G. Charron, M. M. Zhang, J. S. Yount, J. Wilson, A. S. Raghavan, E. Shamir and H. C. Hang, *J. Am. Chem. Soc.*, 2009, **131**, 4967–4975.
- 29 C. M. Hickey, N. R. Wilson and M. Hochstrasser, *Nat. Rev. Mol. Cell Biol.*, 2012, **13**, 755–766.
- 30 X. Xie, X. Wang, W. Liao, R. Fei, N. Wu, X. Cong, Q. Chen, L. Wei, Y. Wang and H. Chen, *Apoptosis*, 2019, **24**, 135–144.
- 31 X. Ou, G. T. Zhang, Z. Xu, J. S. Chen, Y. Xie, J. K. Liu and X. P. Liu, *Pathol. Oncol. Res.*, 2019, **25**, 635–646.
- 32 C. Lin, H. Yan, J. Yang, L. Li, M. Tang, X. Zhao, C. Nie, N. Luo, Y. Wei and Z. Yuan, *Oncotarget*, 2017, **8**, 56281–56295.
- 33 D. Conole, F. Cao, C. W. A. Ende, L. Xue, S. Kantesaria, D. Kang, J. Jin, D. Owen, L. Lohr, M. Schenone, J. D. Majmudar and E. W. Tate, *Angew. Chem., Int. Ed.*, 2023, **62**, e202311190.
- 34 Mission Therapeutics Nominates First Development Candidates Targeting USP30, accessed 14 March 2024, <https://missiontherapeutics.com/mission-therapeutics-nominates-first-development-candidates-targeting-usp30/>.
- 35 N. Panyain, A. Godinat, A. R. Thawani, S. Lachiondo-Ortega, K. Mason, S. Elkhalfifa, L. M. Smith, J. A. Harrigan and E. W. Tate, *RSC Med. Chem.*, 2021, **12**, 1935–1943.
- 36 D. Conole, M. Mondal, J. D. Majmudar and E. W. Tate, *Front. Chem.*, 2019, **7**, 876.

